Slawson R G
Cancer. 1978 Nov;42(5):2216-23. doi: 10.1002/1097-0142(197811)42:5<2216::aid-cncr2820420520>3.0.co;2-d.
79 patients with germinal tumors of the testes were treated at the University of Maryland Radiation Therapy Clinic between January 1, 1957 and December 31, 1973. 32 of 33 patients with stage I seminoma had disease controlled for a minimum of three years for a 96.9% 3 year disease-free determinant survival. 4 of 4 patients with stage I carcinoma were treated, two after negative node dissection, and all survived. 15 of 21 patients with stage II seminoma survived for 3 year disease-free Berkson-Gage actuarial survival of 68.5%, 9 of 21 stage II carcinomas, 18 of whom had had positive node dis-sections, survived for a 3 year disease-free Berkson-Gage actuarial survival of 42.8%. Benefit of adjuvant irradiation of the mediastinum and supraclavicular regions is demonstrated for stage II seminomas where 7/8 patients receiving prophylaxis demonstrated a 100% 3 year disease-free Berkson-Gage actuarial survival as opposed to the 50.4% in the 7/13 patients surviving without adjuvant therapy. This benefit is reaffirmed, although more tenuously, by the 71.4% 3 year disease-free Berkson-Gage actuarial survival demonstrated by the 5 of 7 stage II carcinoma patients receiving adjuvant therapy as opposed to the 28.2% demonstrated by the 4 of 14 patients surviving who did not receive adjuvant therapy.
1957年1月1日至1973年12月31日期间，79例睾丸生殖细胞瘤患者在马里兰大学放射治疗诊所接受了治疗。33例I期精原细胞瘤患者中有32例疾病得到控制至少三年，三年无病决定生存率为96.9%。4例I期癌患者全部接受了治疗，其中2例在淋巴结清扫阴性后接受治疗，均存活。21例II期精原细胞瘤患者中有15例存活三年，无病的伯克森-盖奇精算生存率为68.5%；21例II期癌患者中有9例存活，其中18例淋巴结清扫阳性，三年无病的伯克森-盖奇精算生存率为42.8%。对于II期精原细胞瘤，纵隔和锁骨上区域辅助放疗的益处得到了证明，接受预防治疗的8例患者中有7例三年无病的伯克森-盖奇精算生存率为100%，而未接受辅助治疗存活的13例患者中这一比例为50.4%。7例接受辅助治疗的II期癌患者中有5例三年无病的伯克森-盖奇精算生存率为71.4%，而未接受辅助治疗存活的14例患者中有4例这一比例为28.2%，这再次证明了辅助放疗的益处，尽管不太明显。
